My site

Doha, Qatar-Thursday 7 November 2019 [ AETOS Wire ]

The polls have closed, and the public votes are currently being counted to reveal the winner of Qatar Foundation’s edutainment show Stars of Science Season 11. The three finalists – Abdulrahman Saleh Kamis, Nuha Abu Yousef, and Youssef El Azouzi – have worked tirelessly for the past few months to perfect their inventions, but they will have to wait to hear who the public and the jury have chosen as the Arab region’s top innovator in tonight’s episode. Tune in for the live Grand Final and support your favorite innovator and invention.

Abdulrahman Saleh Khamis, the Qatari engineer, wants to help young and newly converted Muslims learn how to better perform their Islamic prayers. Nuha Abu Yousef, the Jordanian Ophthalmologist, seeks to allow patients with afflicted facial muscles regain control over their affected upper and lower eyelids with her Active Lazy Eyelid Sticker. While Youssef E ... Read more »

 New Fido X4 Provides Versatile, Intelligent Sensing on the Frontlines

ARLINGTON, Va.-Wednesday 6 November 2019 [ AETOS Wire ]

(BUSINESS WIRE) -- FLIR Systems, Inc. (NASDAQ: FLIR) today announced the launch of the FLIR Fido® X4, the newest, most advanced version of its premium handheld explosives trace detector. The Fido X4 delivers unmatched sensitivity for a broad range of explosives, so users can easily detect threats at levels other devices cannot.

FLIR Systems’ TrueTrace® detection technology features a new five-channel sensor array that delivers expanded threat coverage. TrueTrace can accurately detect a wide range of explosives at nanogram to sub-nanogram levels – including military, commercial, improvised, and homemade explosives – allowing users to gain actionable intelligence through identification of threats in as little as ten seconds.

A FLIR PackBot® Hardware Integration Kit will sync the Fido X4 with th ... Read more »

LACHEN, Switzerland-Wednesday 6 November 2019 [ AETOS Wire ]

(BUSINESS WIRE)-- Octapharma announced today that the human fibrinogen concentrate fibryga® has received approval for use in treatment of acquired fibrinogen deficiency (AFD) in 15 European countries. The approval extends the market authorisation for fibryga®, which is already approved for use in patients with congenital fibrinogen deficiency. The addition represents a major milestone for bleeding management in critical care settings.

Fibrinogen is a coagulation factor essential for blood clotting, and therefore to stop excessive bleeding. Unlike with rare congenital fibrinogen deficiencies, AFD arises when excessive blood loss, and so clotting, caused by trauma or major surgery use up the fibrinogen reserves in the blood. Fibrinogen replacement is a recommended first line therapy in the management of patients developing complications from uncontrolled bleeding.

Fibryga® is a highly puri ... Read more »

INCHEON, Korea.-Wednesday 6 November 2019 [ AETOS Wire ]

    Agreement with Biogen covers Samsung Bioepis’ biosimilar candidates in pre-clinical and clinical development, which reference two widely-used biologic medicines in ophthalmology: ranibizumab and aflibercept
    Includes an option for Biogen to extend existing commercialization agreement for Samsung Bioepis’ anti-TNF medicines in Europe – BENEPALI™ (etanercept), FLIXABI™ (infliximab), and IMRALDI™ (adalimumab) – which have treated over 180,000 patients across Europei
    Samsung Bioepis continues its commitment to increasing patient access to high-quality medicines, by expanding its efforts to ophthalmology, in addition to immunology, oncology, and hematology  

(BUSINESS WIRE)-- Samsung Bioepis Co., Ltd. announced today that it has entered into a new commercialization agreement with Biogen (Nasdaq: BIIB) f ... Read more »

− Ongoing Phase 1/2a Study of CD19 CAR-NK with Pivotal Study Expected to Enroll Patients in 2021
− Potential to be the First CAR Cell Therapy Approved for Outpatient Administration

HOUSTON & OSAKA, Japan.-Wednesday 6 November 2019 [ AETOS Wire ]

(BUSINESS WIRE)-- The University of Texas MD Anderson Cancer Center and Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced an exclusive license agreement and research agreement to develop cord blood-derived chimeric antigen receptor-directed natural killer (CAR NK)-cell therapies, ‘armored’ with IL-15, for the treatment of B-cell malignancies and other cancers.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191105005250/en/

Under the agreement, Takeda will receive access to MD Anderson’s CAR NK platform and the exclusive rights to develop and commercialize up to fo ... Read more »

NEW YORK-Tuesday 5 November 2019 [ AETOS Wire ]

(BUSINESS WIRE) -- MSCI Inc. (NYSE: MSCI), a leading provider of critical decision support tools and services for the global investment community, announced today that it is proposing to issue $500.0 million aggregate amount of senior notes due 2029 (the “notes”) in a private offering that is exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”). The notes will mature in November 2029. The proposed offering is subject to market and other conditions. If the offering is successfully placed, MSCI intends to use the net proceeds from the offering for general corporate purposes, including, without limitation, buybacks of its common stock and potential acquisitions. The notes will be senior unsecured obligations of MSCI and will be guaranteed by MSCI and certain of its domestic subsidiaries.

The notes are being offered only to (i) persons reasonably ... Read more »

LACHEN, Switzerland-Saturday 2 November 2019 [ AETOS Wire ]

(BUSINESS WIRE)-- Octapharma has announced the publication of new data demonstrating that the fibrinogen concentrate fibryga® is an effective alternative to cryoprecipitate for patients with severe bleeding during cardiac surgery. The data were recently published in the Journal of the American Medical Association (JAMA).1

Excessive bleeding is a major concern during surgery, and excessive blood loss and/or clotting factor consumption can lead to deficiency in the coagulation factor fibrinogen. This acquired fibrinogen deficiency (AFD) can be treated with plasma-derived cryoprecipitate or with fibrinogen concentrates. Data on the use of fibrinogen concentrates in AFD have been limited until now. fibryga® is a highly purified, dual pathogen-inactivated, lyophilised human fibrinogen concentrate for intravenous infusion, with rapid reconstitution for effective correction of fibrinogen deficiency.

... Read more »

SAN FRANCISCO-Wednesday 6 November 2019 [ AETOS Wire ]

(BUSINESS WIRE) -- Andersen Global now has a presence in Serbia through a Collaboration Agreement with Belgrade-based Joksović, Stojanović & Partners (JSP). The team of 12 partners provides legal guidance to public entities and a large number of international corporate clients. Its practice areas include corporate and commercial law, tax, aviation, capital markets, competition, dispute resolution, employment, energy, information technology, intellectual property, insurance, mergers and acquisitions, real estate, and public procurement.

“We are proud of the ongoing resourcefulness, reliability and professional insight we provide to clients and want to continue to offer our expertise to clients not only locally, but internationally as well,” said Dragan Psodorov, Office Managing Director of JSP. “Our values and goals align well with those of the Andersen Global international organization, and ... Read more »